News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aevi Genomic Medicine (GNMX) Reports Second Quarter 2017 Financial Results



8/10/2017 1:31:46 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
PHILADELPHIA, Aug. 9, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the quarter ended June 30, 2017 and provided a corporate update.

Second Quarter Corporate Highlights

Initiating Phase 2 clinical trial in contactin-4 mutation-positive Attention Deficit Hyperactivity Disorder ("CNTN4+ ADHD") (Part A) to confirm genetic responders to AEVI-001. Patient screening is anticipated to begin in the third quarter of 2017 and data is expected by mid-2018.

Read at PR Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES